Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.…
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
Conexeu Sciences (NASDAQ: CNXU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.550 USD on 20 November 2026. Its 52-week range is 1.480 USD to 18.79 USD: the price is 91.8% below the high and 4.7% above the low.
Its market capitalisation is 47.79M USD.
Conexeu Sciences reports return on equity of -53.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.52M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 22 January 2027.